LMR Partners’s Outlook Therapeutics OTLK Stock Holding History

LMR Partners’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,749	Closed	-$124K	–	1272
2021 Q1	$124K	Buy	+2,749	New	+$105K	﹤0.01%	838

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

LMR Partners's OTLK Position: Q2 2021 in Review

LMR Partners sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 2,749 shares — an estimated $124K sold.

LMR Partners first reported a position in OTLK in Q1 2021 and held it in 1 quarter. The position peaked at $124K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

LMR Partners reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
LMR Partners sold 2,749 Outlook Therapeutics shares in Q2 2021, an estimated $124K.
LMR Partners first reported a position in Outlook Therapeutics in Q1 2021 and held it in 1 quarter.
LMR Partners's Outlook Therapeutics position peaked at $124K in Q1 2021.
63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on LMR Partners's 13F filing for Q2 2021, filed 16 Aug 2021.